Loading clinical trials...
Loading clinical trials...
Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP
São Paulo, São Paulo, Brazil
Start Date
June 5, 2017
Primary Completion Date
June 1, 2019
Completion Date
June 1, 2020
Last Updated
July 11, 2017
58
ESTIMATED participants
Hypofractionated radiation therapy
RADIATION
Lead Sponsor
Instituto do Cancer do Estado de São Paulo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07100730